He/him/his
Omange WR, Varco-Merth BD, Fadeyi O, Marenco A, Takata H, Duell DM, Goodwin WD, Armitage P, Fennessey CM, Kose E, Immonen TT, Kosmider E, Bosche WJ, Fast R, Homick C, Oswald K, Shoemaker R, Bochart R, MacAllister R, Labriola CS, Smedley JV, Axthelm MK, Edlefsen PT, Keele BF, Lifson JD, Gergen J, Petsch B, Rauch S, Picker LJ, Okoye AA. (2026). Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound. The Journal of clinical investigation
Ellis AL, Stauss M, Barros Tiburcio P, Emmen IE, Edlefsen PT, Kosmider E, Barlow S, Goss M, Temte JL, Stachler E, McMahon K, Sabeti P, O'Connor DH, O'Connor SL. (2026). Adaptation of the multiplexed CRISPR-Cas13 CARMEN RVP assay for longitudinal detection of respiratory pathogens from air samples. Applied and environmental microbiology
Mullins JI, Deng W, Giorgi EE, Magaret CA, Rolland M, Bhattacharya T, Westfall DH, Yssel AEJ, Bumgarner RE, Murrell B, Ndung'u T, Robb ML, Rossenkhan R, Edlefsen PT, Dong KL, Chen L, Gwashu-Nyangiwe A, Zhao H, Thebus R, Ndabambi N, Galvao B, Sawe F, Nitayaphan S, York T, Matten D, Murrell H, Pankow AP, Juraska M, Ludwig J, Hural J, Cohen MS, Corey L, McElrath MJ, Gilbert PB, Williamson C. (2026). Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection. Nature communications, 17(1)
Petersen GL, Edlefsen PT, Li X, Morrison R, Kabyemela E, Nelson JL, Duffy PE, Fried M, Harrington WE. (2026). Maternal microchimerism at birth associates with reduced odds of non-malarial fever and respiratory tract infections in Tanzanian children. PLOS global public health, 6(5)
Williamson C, Moodley C, Magaret CA, Giorgi EE, Rolland M, Westfall DH, Yssel A, Deng W, Rossenkhan R, Mkhize NN, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, York T, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Cohen P, Lambson B, Kaldine H, Bhebhe S, Juraska M, Bai H, deCamp AC, Miner MD, Ludwig J, Molitor C, Beaume N, Matten D, Huang Y, Zhang L, Reeves DB, Mayer B, Karuna ST, Hural JA, Morris L, Montefiori D, Bumgarner RE, Moore PL, Edlefsen PT, Edupuganti S, Mgodi N, McElrath MJ, Cohen MS, Corey L, Gilbert PB, Mullins JI. (2026). Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials. Nature communications
Williamson C, Curry L, Mkhize NN, Giorgi EE, Magaret CA, Lambson BE, Hons SB, Kaldine H, Moyo-Gwete T, Rolland M, Rossenkhan R, Garcia NMG, Moodley C, Yssel A, Huang Y, Marsden AA, Reeves DB, Mayer BT, Bumgarner RE, Beaume N, Westfall DH, Juraska M, deCamp AC, Murrell H, Bai H, Deng W, Pankow AP, Bhattacharya T, York T, Ndabambi N, Chen L, Zhao H, Gwashu-Nyangiri A, Thebus R, Cohen P, Murrell B, Karuna S, Hural J, Mgodi N, Edupuganti S, Morris L, Montefiori D, McElrath MJ, Cohen MS, Corey L, Edlefsen PT, Gilbert PB, Moore PL, Mullins JI. (2025). VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials. bioRxiv : the preprint server for biology
Hansen SG, Schell JB, Marshall EE, Ojha S, Feltham S, Morrow D, Hughes CM, Gilbride RM, Ford JC, Cleveland-Rubeor HC, McArdle MR, Whitmer T, Barber-Axthelm A, Bochart R, Smedley J, Oswald K, Fast R, Shoemaker R, Kosmider E, Edlefsen PT, Lifson JD, Malouli D, Früh K, Picker LJ. (2025). Glycoprotein L-deleted single-cycle rhesus cytomegalovirus vectors elicit MHC-E-restricted CD8+ T cells that protect against SIV. Journal of immunology (Baltimore, Md. : 1950)
Fredericks MN, Kolodner Z, Waalkes A, Sawatzki K, Hao L, Long DR, Penewit K, Midkiff CC, McCormick CJ, Beraki S, Edlefsen PT, Barrow J, Greninger AL, Gale M, Blair RV, Salipante SJ, Fuller DH, O'Connor MA. (2025). SIV/SARS-CoV-2 co-infection in rhesus macaques impacts viral shedding, host immunity, the microbiome, and viral evolution. Research square
Fredericks MN, Kolodner Z, Waalkes A, Sawatzki K, Hao L, Long DR, Penewit K, Midkiff CC, McCormick CJ, Beraki S, Edlefsen PT, Barrow J, Greninger AL, Gale M, Blair RV, Salipante SJ, Fuller DH, O'Connor MA. (2025). SIV/SARS-CoV-2 coinfection in rhesus macaques impacts viral shedding, host immunity, the microbiome, and viral evolution. Frontiers in immunology, (16)
Rossenkhan R, Giorgi EE, Shao D, Ludwig J, Labuschagne P, Magaret CA, Ndung'u T, Muema D, Gounder K, Dong KL, Walker BD, Rolland M, Robb ML, Eller LA, Sawe F, Nitayaphan S, Grebe E, Busch MP, Delaney KP, Facente S, Carpp LN, deCamp AC, Huang Y, Korber B, Juraska M, Rudnicki E, Kosmider E, Reeves DB, Mayer BT, Hural J, Deng W, Westfall DH, Yssel A, Matten D, Bhattacharya T, Corey L, Gilbert PB, Williamson C, Mullins JI, Edlefsen PT. (2025). Bayesian estimation of HIV acquisition dates for prevention trials. mBio
Tisoncik-Go J, Lewis TB, Whitmore LS, Voss K, Niemeyer S, Dai J, Kim P, Hubbell K, Iwayama N, Ahrens C, Wangari S, Murnane R, Edlefsen PT, Guerriero KA, Gale M Jr., Fuller DH, O'Connor MA. (2025). Persistent innate immune dysfunction and ZIKV replication in the gastrointestinal tract during SIV infection in pigtail macaques. Frontiers in immunology, (16)
Dubois MM, Jao J, Sun S, Legbedze J, Schenkel S, Mmasa N, Kgole SW, Masasa G, Happel AU, Iwase SC, Haghighat R, Moyo S, Sharma TS, Edlefsen PT, Shao D, Jaspan H, Powis KM. (2024). Infectious Morbidity and All-cause Mortality of Infants HIV-exposed Uninfected Compared to Infants HIV-unexposed Uninfected in Botswana. The Pediatric infectious disease journal
Tisoncik-Go J, Lewis TB, Whitmore LS, Voss K, Niemeyer S, Dai J, Kim P, Hubbell K, Iwayama N, Ahrens C, Wangari S, Murnane R, Edlefsen PT, Guerriero KA, Gale M Jr., Fuller DH, O'Connor MA. (2024). Chronic innate immune impairment and ZIKV persistence in the gastrointestinal tract during SIV infection in pigtail macaques. bioRxiv : the preprint server for biology
Varco-Merth B, Chaunzwa M, Duell DM, Marenco A, Goodwin W, Dannay R, Nekorchuk M, Shao D, Busman-Sahay K, Fennessey CM, Silipino L, Hull M, Bosche WJ, Fast R, Oswald K, Shoemaker R, Bochart R, MacAllister R, Labriola CS, Smedley JV, Axthelm MK, Davenport MP, Edlefsen PT, Estes JD, Keele BF, Lifson JD, Lewin SR, Picker LJ, Okoye AA. (2024). Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence. PLoS pathogens, 20(8)
Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S. (2024). Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nature communications, 15(1)
Juraska M, Bai H, deCamp AC, Magaret CA, Li L, Gillespie K, Carpp LN, Giorgi EE, Ludwig J, Molitor C, Hudson A, Williamson BD, Espy N, Simpkins B, Rudnicki E, Shao D, Rossenkhan R, Edlefsen PT, Westfall DH, Deng W, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, Yssel A, Matten D, York T, Beaume N, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Karuna ST, Morris L, Montefiori DC, Hural JA, Cohen MS, Corey L, Rolland M, Gilbert PB, Williamson C, Mullins JI. (2024). Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proceedings of the National Academy of Sciences of the United States of America, 121(4)
Kosmider E, Wallner J, Gervassi A, Bender Ignacio RA, Pinto-Santini D, Gornalusse G, Pandey U, Hladik F, Edlefsen PT, Lama JR, Duerr AC, Frenkel LM. (2024). Observational study of effects of HIV acquisition and antiretroviral treatment on biomarkers of systemic immune activation. PloS one, 19(7)
Joy J, Gervassi AL, Chen L, Kirshenbaum B, Styrchak S, Ko D, McLaughlin S, Shao D, Kosmider E, Edlefsen PT, Maenza J, Collier AC, Mullins JI, Horton H, Frenkel LM. (2024). Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiation. The Journal of clinical investigation
Peters MQ, Domenjo-Vila E, Carlson M, Armistead B, Edlefsen PT, Gasper M, Dabee S, Whidbey C, Jaspan HB, Prlic M, Harrington WE. (2024). A Noninvasive Method to Sample Immune Cells in the Lower Female Genital Tract Using Menstrual Discs. ImmunoHorizons, 8(2)
O'Connor MA, Hawman DW, Meade-White K, Leventhal S, Song W, Randall S, Archer J, Lewis TB, Brown B, Fredericks MN, Sprouse KR, Tunggal HC, Maughan M, Iwayama N, Ahrens C, Garrison W, Wangari S, Guerriero KA, Hanley P, Lovaglio J, Saturday G, Veesler D, Edlefsen PT, Khandhar AP, Feldmann H, Fuller DH, Erasmus JH. (2023). A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. PLoS pathogens, 19(4)
Tisoncik-Go J, Voss KM, Lewis TB, Muruato AE, Kuller L, Finn EE, Betancourt D, Wangari S, Ahrens J, Iwayama N, Grant RF, Murnane RD, Edlefsen PT, Fuller DH, Barber GN, Gale M Jr., O'Connor MA. (2023). Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina. Frontiers in virology (Lausanne, Switzerland), (3)
Vigdorovich V, Patel H, Watson A, Raappana A, Reynolds L, Selman W, Beeman S, Edlefsen PT, Kappe SHI, Sather DN. (2023). Coimmunization with Preerythrocytic Antigens alongside Circumsporozoite Protein Can Enhance Sterile Protection against Plasmodium Sporozoite Infection. Microbiology spectrum, 11(2)
Plumlee CR, Barrett HW, Shao DE, Lien KA, Cross LM, Cohen SB, Edlefsen PT, Urdahl KB. (2023). Assessing vaccine-mediated protection in an ultra-low dose Mycobacterium tuberculosis murine model. PLoS pathogens, 19(11)
Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S. (2023). High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nature communications, 14(1)
Seaton KE, Huang Y, Karuna S, Heptinstall JR, Brackett C, Chiong K, Zhang L, Yates NL, Sampson M, Rudnicki E, Juraska M, deCamp AC, Edlefsen PT, Mullins JI, Williamson C, Rossenkhan R, Giorgi EE, Kenny A, Angier H, Randhawa A, Weiner JA, Rojas M, Sarzotti-Kelsoe M, Zhang L, Sawant S, Ackerman ME, McDermott AB, Mascola JR, Hural J, McElrath MJ, Andrew P, Hidalgo JA, Clark J, Laher F, Orrell C, Frank I, Gonzales P, Edupuganti S, Mgodi N, Corey L, Morris L, Montefiori D, Cohen MS, Gilbert PB, Tomaras GD. (2023). Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine, (93)
Iwase SC, Edlefsen PT, Bhebhe L, Motsumi K, Moyo S, Happel AU, Shao D, Mmasa N, Schenkel S, Gasper MA, Dubois M, Files MA, Seshadri C, Duffy F, Aitchison J, Netea MG, Jao J, Cameron DW, Gray CM, Jaspan HB, Powis KM. (2023). T-SPOT.TB reactivity in Southern African children with and without in utero HIV exposure. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Varco-Merth BD, Brantley W, Marenco A, Duell DD, Fachko DN, Richardson B, Busman-Sahay K, Shao D, Flores W, Engelman K, Fukazawa Y, Wong SW, Skalsky RL, Smedley J, Axthelm MK, Lifson JD, Estes JD, Edlefsen PT, Picker L, Cameron CM, Henrich TJ, Okoye AA. (2022). Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy. The Journal of clinical investigation
Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, Giorgi EE, Korber B, Edlefsen PT, Rossenkhan R, Juraska M, Rudnicki E, Kochar N, Huang Y, Carpp LN, Barouch DH, Mkhize NN, Hermanus T, Kgagudi P, Bekker V, Kaldine H, Mapengo RE, Eaton A, Domin E, West C, Feng W, Tang H, Seaton KE, Heptinstall J, Brackett C, Chiong K, Tomaras GD, Andrew P, Mayer BT, Reeves DB, Sobieszczyk ME, Garrett N, Sanchez J, Gay C, Makhema J, Williamson C, Mullins JI, Hural J, Cohen MS, Corey L, Montefiori DC, Morris L. (2022). Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature medicine
Hansen SG, Hancock MH, Malouli D, Marshall EE, Hughes CM, Randall KT, Morrow D, Ford JC, Gilbride RM, Selseth AN, Trethewy RE, Bishop LM, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Silipino L, Nekorchuk M, Busman-Sahay K, Estes JD, Axthelm MK, Smedley J, Shao D, Edlefsen PT, Lifson JD, Früh K, Nelson JA, Picker LJ. (2022). Myeloid cell tropism enables MHC-E-restricted CD8(+) T cell priming and vaccine efficacy by the RhCMV/SIV vaccine. Science immunology, 7(72)
Harwood OE, Balgeman AJ, Weaver AJ, Ellis-Connell AL, Weiler AM, Erickson KN, Matschke LM, Golfinos AE, Vezys V, Skinner PJ, Safrit JT, Edlefsen PT, Reynolds MR, Friedrich TC, O'Connor SL. (2022). Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803. Journal of virology
Ford ES, Sholukh AM, Boytz R, Carmack SS, Klock A, Phasouk K, Shao D, Rossenkhan R, Edlefsen PT, Peng T, Johnston C, Wald A, Zhu J, Corey L. (2021). B cells, antibody-secreting cells and virus-specific antibodies respond to herpes simplex virus-2 reactivation in skin. The Journal of clinical investigation
Malouli D, Hansen SG, Hancock MH, Hughes CM, Ford JC, Gilbride RM, Ventura AB, Morrow D, Randall KT, Taher H, Uebelhoer LS, McArdle MR, Papen CR, Espinosa Trethewy R, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Greene JM, Axthelm MK, Shao J, Edlefsen PT, Grey F, Nelson JA, Lifson JD, Streblow D, Sacha JB, Früh K, Picker LJ. (2021). Cytomegaloviral determinants of CD8(+) T cell programming and RhCMV/SIV vaccine efficacy. Science immunology, 6(57)
Verweij M, Hansen SG, Iyer R, John N, Malouli D, Morrow D, Scholz I, Womack J, Abdulhaqq S, Gilbride RM, Hughes CM, Ventura AB, Ford JC, Selseth AN, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Shao J, Sacha JB, Axthelm MK, Edlefsen PT, Lifson JD, Picker LJ, Früh K. (2021). Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy. Science (New York, N.Y.)
Okoye AA, Duell DD, Fukazawa Y, Varco-Merth B, Marenco A, Behrens H, Chaunzwa TM, Selseth AN, Gilbride RM, Shao J, Edlefsen PT, Geleziunas R, Pinkevych M, Davenport MP, Busman-Sahay K, Nekorchuk MD, Park H, Smedley JV, Axthelm MK, Estes JD, Hansen SG, Keele BF, Lifson JD, Picker LJ. (2021). CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification. The Journal of clinical investigation
Kidzeru E, Gasper MA, Shao D, Edlefsen PT, Lejarcegui N, Havyarimana E, Urdahl K, Gantt S, Horton H, Jaspan H, Gervassi A. (2021). Myeloid-derived suppressor cells and their association with vaccine immunogenicity in South African infants. Journal of leukocyte biology
Lewitus E, Sanders-Buell E, Bose M, O'Sullivan AM, Poltavee K, Li Y, Bai H, Mdluli T, Donofrio G, Slike B, Zhao H, Wong K, Chen L, Miller S, Lee J, Ahani B, Lepore S, Muhammad S, Grande R, Tran U, Dussupt V, Mendez-Rivera L, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Janes H, Gilbert PB, Gramzinski R, Vasan S, Robb ML, Michael NL, Krebs SJ, Herbeck JT, Edlefsen PT, Mullins JI, Kim JH, Tovanabutra S, Rolland M. (2021). RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus evolution, 7(2)
Barrenäs F, Hansen SG, Law L, Driscoll C, Green RR, Smith E, Chang J, Golez I, Urion T, Peng X, Whitmore L, Newhouse D, Hughes CM, Morrow D, Randall KT, Selseth AN, Ford JC, Gilbride RM, Randall BE, Ainslie E, Oswald K, Shoemaker R, Fast R, Bosche WJ, Axthelm MK, Fukazawa Y, Pavlakis GN, Felber BK, Fourati S, Sekaly RP, Lifson JD, Komorowski J, Kosmider E, Shao D, Song W, Edlefsen PT, Picker LJ, Gale M Jr.. (2021). Interleukin-15 response signature predicts RhCMV/SIV vaccine efficacy. PLoS pathogens, 17(7)
Rolland M, Tovanabutra S, Dearlove B, Li Y, Owen CL, Lewitus E, Sanders-Buell E, Bose M, O'Sullivan A, Rossenkhan R, Labuschagne JPL, Edlefsen PT, Reeves DB, Kijak G, Miller S, Poltavee K, Lee J, Bonar L, Harbolick E, Ahani B, Pham P, Kibuuka H, Maganga L, Nitayaphan S, Sawe FK, Eller LA, Gramzinski R, Kim JH, Michael NL, Robb ML,. (2020). Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand. PLoS pathogens, 16(2)
Taher H, Mahyari E, Kreklywich C, Uebelhoer LS, McArdle MR, Moström MJ, Bhusari A, Nekorchuk M, E X, Whitmer T, Scheef EA, Sprehe LM, Roberts DL, Hughes CM, Jackson KA, Selseth AN, Ventura AB, Cleveland-Rubeor HC, Yue Y, Schmidt KA, Shao J, Edlefsen PT, Smedley J, Kowalik TF, Stanton RJ, Axthelm MK, Estes JD, Hansen SG, Kaur A, Barry PA, Bimber BN, Picker LJ, Streblow DN, Früh K, Malouli D. (2020). In vitro and in vivo characterization of a recombinant rhesus cytomegalovirus containing a complete genome. PLoS pathogens, 16(11)
Jacob PE, Gong R, Edlefsen PT, Dempster AP. (2021). A Gibbs sampler for a class of random convex polytopes. Journal of the American Statistical Association, 116(535)
Curlin ME, Shao J, Diaz G, Edlefsen PT, Novak RM, Mayer KH, Allen M, Morgan C, Maenza J, Buchbinder S, Keefer MC, Rosa SC, Corey L, Duerr A, . (2020). Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. Vaccine, 38(36)
Mdluli T, Jian N, Slike B, Paquin-Proulx D, Donofrio G, Alrubayyi A, Gift S, Grande R, Bryson M, Lee A, Dussupt V, Mendez-Riveria L, Sanders-Buell E, Chenine AL, Tran U, Li Y, Brown E, Edlefsen PT, O'Connell R, Gilbert P, Nitayaphan S, Pitisuttihum P, Rerks-Ngarm S, Robb ML, Gramzinski R, Alter G, Tovanabutra S, Georgiev IS, Ackerman ME, Polonis VR, Vasan S, Michael NL, Kim JH, Eller MA, Krebs SJ, Rolland M. (2020). RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS pathogens, 16(12)
Magaret CA, Benkeser DC, Williamson BD, Borate BR, Carpp LN, Georgiev IS, Setliff I, Dingens AS, Simon N, Carone M, Simpkins C, Montefiori D, Alter G, Yu WH, Juraska M, Edlefsen PT, Karuna S, Mgodi NM, Edugupanti S, Gilbert PB. (2019). Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. PLoS computational biology, 15(4)
Hansen SG, Womack J, Scholz I, Renner A, Edgel KA, Xu G, Ford JC, Grey M, St Laurent B, Turner JM, Planer S, Legasse AW, Richie TL, Aguiar JC, Axthelm MK, Villasante ED, Weiss W, Edlefsen PT, Picker LJ, Früh K. (2019). Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge. PloS one, 14(1)
Marshall EE, Malouli D, Hansen SG, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Selseth AN, Ford JC, Burke D, Kreklywich CN, Womack J, Legasse AW, Axthelm MK, Kahl C, Streblow D, Edlefsen PT, Picker LJ, Früh K. (2019). Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity. Science translational medicine, 11(501)
Hansen SG, Marshall EE, Malouli D, Ventura AB, Hughes CM, Ainslie E, Ford JC, Morrow D, Gilbride RM, Bae JY, Legasse AW, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Womack J, Shao J, Edlefsen PT, Reed JS, Burwitz BJ, Sacha JB, Axthelm MK, Früh K, Lifson JD, Picker LJ. (2019). A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Science translational medicine, 11(501)
Rossenkhan R, Rolland M, Labuschagne JPL, Ferreira RC, Magaret CA, Carpp LN, Matsen Iv FA, Huang Y, Rudnicki EE, Zhang Y, Ndabambi N, Logan M, Holzman T, Abrahams MR, Anthony C, Tovanabutra S, Warth C, Botha G, Matten D, Nitayaphan S, Kibuuka H, Sawe FK, Chopera D, Eller LA, Travers S, Robb ML, Williamson C, Gilbert PB, Edlefsen PT. (2019). Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy Assessment. Viruses, 11(7)
Juraska M, Magaret CA, Shao J, Carpp LN, Fiore-Gartland AJ, Benkeser D, Girerd-Chambaz Y, Langevin E, Frago C, Guy B, Jackson N, Duong Thi Hue K, Simmons CP, Edlefsen PT, Gilbert PB. (2018). Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proceedings of the National Academy of Sciences of the United States of America, 115(36)
O'Connor MA, Tisoncik-Go J, Lewis TB, Miller CJ, Bratt D, Moats CR, Edlefsen PT, Smedley J, Klatt NR, Gale M Jr., Fuller DH. (2018). Early cellular innate immune responses drive Zika viral persistence and tissue tropism in pigtail macaques. Nature communications, 9(1)
Wood LF, Brown BP, Lennard K, Karaoz U, Havyarimana E, Passmore JS, Hesseling AC, Edlefsen PT, Kuhn L, Mulder N, Brodie EL, Sodora DL, Jaspan HB. (2018). Feeding-Related Gut Microbial Composition Associates With Peripheral T-Cell Activation and Mucosal Gene Expression in African Infants. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 67(8)
Hansen SG, Zak DE, Xu G, Ford JC, Marshall EE, Malouli D, Gilbride RM, Hughes CM, Ventura AB, Ainslie E, Randall KT, Selseth AN, Rundstrom P, Herlache L, Lewis MS, Park H, Planer SL, Turner JM, Fischer M, Armstrong C, Zweig RC, Valvo J, Braun JM, Shankar S, Lu L, Sylwester AW, Legasse AW, Messerle M, Jarvis MA, Amon LM, Aderem A, Alter G, Laddy DJ, Stone M, Bonavia A, Evans TG, Axthelm MK, Früh K, Edlefsen PT, Picker LJ. (2018). Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. Nature medicine, 24(2)
Okoye AA, Hansen SG, Vaidya M, Fukazawa Y, Park H, Duell DM, Lum R, Hughes CM, Ventura AB, Ainslie E, Ford JC, Morrow D, Gilbride RM, Legasse AW, Hesselgesser J, Geleziunas R, Li Y, Oswald K, Shoemaker R, Fast R, Bosche WJ, Borate BR, Edlefsen PT, Axthelm MK, Picker LJ, Lifson JD. (2018). Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nature medicine, 24(9)
deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB. (2017). Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. PloS one, 12(11)
Herbeck JT, Peebles K, Edlefsen PT, Rolland M, Murphy JT, Gottlieb GS, Abernethy N, Mullins JI, Mittler JE, Goodreau SM. (2018). HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine. Vaccine, 36(4)
Fiore-Gartland A, Kullman N, deCamp AC, Clenaghan G, Yang W, Magaret CA, Edlefsen PT, Gilbert PB. (2017). SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials. Bioinformatics (Oxford, England), 33(15)
Rossenkhan R, MacLeod IJ, Brumme ZL, Magaret CA, Sebunya TK, Musonda R, Gashe BA, Edlefsen PT, Novitsky V, Essex M. (2016). Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection. AIDS research and human retroviruses, 32(10-11)
Edlefsen PT, Birkmann A, Huang ML, Magaret CA, Kee JJ, Diem K, Goldner T, Timmler B, Stoelben S, Ruebsamen-Schaeff H, Zimmermann H, Warren T, Wald A, Corey L. (2016). No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy. The Journal of infectious diseases, 214(2)
Edlefsen PT, Rolland M, Hertz T, Tovanabutra S, Gartland AJ, deCamp AC, Magaret CA, Ahmed H, Gottardo R, Juraska M, McCoy C, Larsen BB, Sanders-Buell E, Carrico C, Menis S, Kijak GH, Bose M, , Arroyo MA, O'Connell RJ, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Robb ML, Kirys T, Georgiev IS, Kwong PD, Scheffler K, Pond SL, Carlson JM, Michael NL, Schief WR, Mullins JI, Kim JH, Gilbert PB. (2015). Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS computational biology, 11(2)
Sterrett S, Learn GH, Edlefsen PT, Haynes BF, Hahn BH, Shaw GM, Bar KJ. (2014). Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. Open forum infectious diseases, 1(2)
Dommaraju K, Kijak G, Carlson JM, Larsen BB, Tovanabutra S, Geraghty DE, Deng W, Maust BS, Edlefsen PT, Sanders-Buell E, Ratto-Kim S, deSouza MS, Rerks-Ngarm S, Nitayaphan S, Pitisuttihum P, Kaewkungwal J, O'Connell RJ, Robb ML, Michael NL, Mullins JI, Kim JH, Rolland M. (2014). CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. PLoS One, 9(10)
Edlefsen PT. (2014). Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis. Computational and mathematical methods in medicine, (2014)
Edlefsen PT, Gilbert PB, Rolland M. (2013). Sieve analysis in HIV-1 vaccine efficacy trials. Current opinion in HIV and AIDS, 8(5)
Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH. (2012). Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature, 490(7420)
Edlefsen PT, Liu JS. (2010). Transposon identification using profile HMMs. BMC Genomics, (11 Suppl 1)
If you’d like to update your profile, please email modifications to questions@midasnetwork.us.